Anbio Biotechnology Announces Closing of Initial Public Offering

Rhea-AI Summary

Anbio Biotechnology has successfully completed its Initial Public Offering (IPO) on the Nasdaq Global Market under the ticker symbol 'NNNN'. The company offered 1,600,000 Class A ordinary shares at $5.00 per share, raising gross proceeds of $8 million before deducting underwriting discounts and related expenses.

Trading commenced on February 19, 2025. The proceeds will be used for expanding sales and distribution networks in strategic markets, research and development initiatives, and working capital purposes. AC Sunshine Securities served as the underwriter for this firm commitment offering.

The IPO was supported by a Form F-1 registration statement filed with the SEC, which became effective on February 18, 2025. Ortoli Rosenstadt LLP and Focus Law served as legal counsel to the company and underwriter, respectively.

Positive

• Successfully raised $8 million in gross proceeds through IPO
• Achieved Nasdaq Global Market listing, providing increased visibility and liquidity
• Clear allocation of funds for strategic growth initiatives and R&D

Negative

• Relatively small IPO size of $8 million may limit growth potential
• Gross proceeds subject to reduction from underwriting discounts and expenses

Insights

Financial Analyst

This IPO represents a strategic but conservative market entry, with Anbio Biotechnology raising $8 million at $5.00 per share. The modest offering size signals a measured approach to public markets, potentially limiting initial dilution while establishing a public trading platform for future capital raises.

Several key aspects warrant attention: First, the choice of a U.S. listing on Nasdaq, despite being a German company, suggests ambitions to tap into the deeper U.S. capital markets and enhance global visibility. Second, the firm commitment underwriting structure provides additional credibility, though the selection of a smaller investment bank (AC Sunshine Securities) may impact initial trading liquidity and institutional coverage.

The stated use of proceeds focuses on three critical areas:

• Sales and distribution network expansion in strategic markets
• Research and development investments
• Working capital and general corporate purposes

For the in vitro diagnostics (IVD) sector, this capital allocation strategy aligns with market penetration objectives, though the relatively small raise may necessitate careful prioritization of initiatives. The timing of this IPO during current market conditions suggests confidence in the company's growth trajectory, but investors should monitor the execution of the stated expansion plans given the initial funding.

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol “NNNN.”

The Company received aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts and other related expenses.

Proceeds from the Offering will be used for expansion of sales and distribution network in the strategically selected markets, research and development, and working capital and general corporate matters.

The Offering was conducted on a firm commitment basis. AC Sunshine Securities LLC acted as the underwriter for the Offering (the “Underwriter”). Ortoli Rosenstadt LLP acted as U.S. counsel to the Company, and Focus Law acted as U.S. counsel to the Underwriter in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) (File Number: 333-284106), as amended, and was declared effective by the SEC on February 18, 2025. The Offering was made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from AC Sunshine Securities LLC by email at prospectus@acsunshine.com, by standard mail to 200 E. Robinson Street, Suite 295, Orlando, FL 32801, or by telephone at +1 (689)-689-9686. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. It is an innovation-driven global diagnostic company offering a diverse portfolio of mature diagnostic assays and five key platforms for biomarker detection, including Fluorescent Immunochromatographic Solution (FIA), Chemiluminescent Immunoassay Solution (ChLIA), Polymerase Chain Reaction Solution (PCR), Lateral Flow Assay Solution (LFIA), and Loop-Mediated Isothermal Amplification Solution (LAMP). These solutions cater to point-of-care settings, laboratory, and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic tools. With a strong global presence across the EU, APAC, and the Americas, the Company’s Conformité Européenne (CE)-marked products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability, and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. For more information, please visit the Company’s website: https://www.anbiobiotechnology.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:
investors@ascent-ir.com

FAQ

How much did Anbio Biotechnology (NNNN) raise in its IPO?

Anbio Biotechnology raised $8 million in gross proceeds through its IPO, offering 1,600,000 Class A ordinary shares at $5.00 per share.

When did NNNN stock begin trading on Nasdaq?

NNNN stock began trading on the Nasdaq Global Market on February 19, 2025.

What is the IPO price for Anbio Biotechnology (NNNN) shares?

The IPO price for Anbio Biotechnology shares was set at $5.00 per Class A Ordinary Share.

How will Anbio Biotechnology (NNNN) use its IPO proceeds?

The IPO proceeds will be used for expanding sales and distribution networks in strategic markets, research and development, and working capital and general corporate purposes.

Who was the underwriter for the NNNN IPO?

AC Sunshine Securities acted as the underwriter for Anbio Biotechnology's IPO.